Starling Oncology
STLN
38 hedge funds and large institutions have $97.2M invested in Starling Oncology in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
91% more capital invested
Capital invested by funds: $50.8M → $97.2M (+$46.3M)
81% more funds holding
Funds holding: 21 → 38 (+17)
18.78% more ownership
Funds ownership: 21.97% → 40.75% (+19%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.2M |
| 2 |
JP Morgan Chase
New York
|
+$6.23M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$4.42M |
| 4 |
KC
Kepos Capital
New York
|
+$4.35M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$4.83M |
| 2 |
OCAM
Owl Creek Asset Management
New York
|
-$2.01M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.46M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$754K |
| 5 |
JG
Jefferies Group
New York
|
-$526K |
STLN Hedge Fund Activity: Q3 2020 in Review
38 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q3 2020, worth a combined $97.2M — up 91% from $50.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STLN positions and 3 closed out — a net gain of 17 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, adding an estimated $15.2M. The largest seller was UBS O'Connor, cutting an estimated $4.83M.
- 38 institutional investors held Starling Oncology (STLN) as of Q3 2020, up from 21 in Q2 2020.
- Funds reported $97.2M of Starling Oncology stock for Q3 2020, up 91% quarter-over-quarter.
- 20 funds opened new Starling Oncology positions in Q3 2020 and 3 closed out, a net change of +17 holders.
- The largest Starling Oncology buyer in Q3 2020 was Millennium Management, an estimated $15.2M added.
- The largest Starling Oncology seller in Q3 2020 was UBS O'Connor, an estimated $4.83M sold.
Based on aggregated 13F filings for Q3 2020.